Hemorrhagic Stroke Treatment Market Size, Share & Industry Analysis, By Drug Type (Antihypertensive, Anti-Coagulants, Anti Convulsants, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Regional Forecast, 2024-2032

Hemorrhagic stroke is the hemorrhage that unexpectedly interrupts the brain’s function. Bleeding can be observed within the brain or amid the brain and skull. This is mainly caused due to rupture in the weakened blood vessels which leads to the low blood supply to the brain leading to the death of cerebral cells. Thus, hemorrhagic stroke is also known as cerebral haemorrhage. There are two types of the intracerebral hemorrhagic stroke where bleeding occurs in the brain and subarachnoid hemorrhage in which bleeding occurs in between brain and membranes that surround it. Bleeding in the brain occurs owing to various health complications such as high blood pressure, stroke, tumour, and others. Hence, hemorrhagic stroke treatment deals with reducing high blood pressure and continuous monitoring of the same. Both types of hemorrhagic stroke have conventional risk factors which include hypertension, cerebral cavernous malfunction, arteriovenous malfunctions, bleeding disorder, head injury, and others are also boosting the market growth during the forecast period. Furthermore, various symptoms of the hemorrhagic stroke include paralysis in any part of the body, speech loss, difficulty in breathing, coma, loss of consciousness, and others are also influencing the market growth.

Major factors that are driving the growth of the market are an increase in the prevalence of hemorrhagic stroke in patients suffering from hypertension, increase in intracerebral hemorrhagic, rise in geriatric population, a rise in chronic diseases, and others. According to, the Global Burden of Disease in 2010 there were about 5.3 million hemorrhagic stroke cases and 80% of these cases wherein low-middle income countries. Moreover, large hemorrhage has a chance of damaging the entire brain hence minimal invasive technique called burr hole is used for clearing imbalance of blood flow in the brain which is also triggering the market growth. Furthermore, advanced diagnostic techniques used for the treatment of hemorrhagic stroke by neurologists that help in faster recovery and proper medication designing is also propelling the market growth. For instance, the usage of nanotechnology in the treatment of Hemorrhagic. Furthermore, various tests such as MRI, magnetic resonance imaging angiography (MRA), and blood tests are also performed to examine the stroke. Additionally, the increase in consumption of antihypertensive drugs also increases the hemorrhagic stroke. This in turn, is influencing the demand for hemorrhagic stroke treatment.

Key Market Driver -

Increasing prevalence of hemorrhagic stroke

Key Market Restraint -

Stringent FDA approvals

However, stringent FDA regulations coupled with high cost of the treatment is anticipated to limit the growth of the market in the near future. Additionally, usage of generic drugs is also restraining the market growth.

Key Players Covered:

Some of the major companies that are present in the global hemorrhagic stroke treatment market are B. Braun Melsungen AG, Medtronic, Bayer AG, Novartis AG, Pfizer Inc, Merck & Co., Inc., GlaxoSmithKline plc, Abbott, and other players.

Antihypertensive drugs are anticipated to boost the market growth. Owing to increase in number of hypertensive patients, a rise in medical professionals preferring these for the reduction of stroke, and others.

Key Insights

• Prevalence of Hemorrhagic Stroke


• Overview of market share analysis


• Regulatory scenario for key countries


• New product launches


• Key industry developments

Regional Analysis:

The global hemorrhagic stroke treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the global hemorrhagic market due to a number of factors such as the increasing prevalence of chronic diseases, increasing prevalence of hemorrhagic stroke, increased healthcare awareness, and others. Europe is considered to be second dominating followed by the Asia Pacific due to increase in geriatric population, increased healthcare infrastructure, improved R& D in countries like China and India, increased government financial support towards conducting more R&D activities, and others. Latin America and Middle East & Africa are expected to experience steady growth.

To gain extensive insights into the market, Request for Customization

Segmentation

Key Industry Developments

• In October 2019, iSchemaView, Inc. Launched newest addition of rapid platform named RAPID ICH. This system uses artificial intelligence to triage non contrast CT and notify clinicians in identifying possibility of intracranial haemorrhage